HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q4 Consumer Health Earnings Preview: GSK, Bayer, RB, And Sanofi

Executive Summary

GSK is looking to close out 2018 strongly as it prepares to launch its Consumer Health JV with Pfizer, while Bayer will be glad to see the back of a tough year. Elsewhere, RB is preparing for life after Rakesh Kapoor and Sanofi is ramping up its push into digital health.

You may also be interested in...



Pfizer Consumer Health True To Form Pending Move To JV With GSK

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

Horlicks Brings Unilever 'Transformative' Nutritional Deal, Market Challenges

Firm's Hindustan Unilever division will merge with s GSK Consumer Healthcare India which has had total sales around €550m so far in 2018, primarily through the Horlicks and Boost brands and with nearly 90% of the revenues in India. Also will acquire 82% stake in GSK Bangladesh and other GSK commercial operations and assets outside India, paying €3.3bn in combination of cash and shares in Hindustan Unilever.

Sanofi’s growth balanced across all geographies

Sanofi enjoyed “balanced growth across all geographies and key categories” at its Consumer Healthcare business in the third quarter, noted group chief executive officer Olivier Brandicourt.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel